KLK3 and posterior cortical atrophy: Based on blood tests (including PSA) and some clinical information, it aims to increase both sensitivity and specificity compared with the PSA, and thereby reduce the number of biopsies required without compromising the ability to diagnose clinically significant PCa (Gleason score of at least 7) [13–15].